We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals

15 hedge funds and large institutions have $175K invested in Sonoma Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more capital inflows, than outflows

Capital inflows: $78.5K | Capital outflows: $61.1K

0.12% more ownership

Funds ownership: 3.16% → 3.28% (+0.12%)

12% less funds holding

Funds holding: 17 → 15 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SNOA Hedge Fund Activity: Q2 2023 in Review

15 of the 6,391 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2023, worth a combined $175K — up 22% from $144K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SNOA and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $53.5K. The largest seller was Millennium Management, exiting entirely with an estimated $23K sold.

  • 15 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2023, down from 17 in Q1 2023.
  • Funds reported $175K of Sonoma Pharmaceuticals stock for Q2 2023, up 22% quarter-over-quarter.
  • 2 funds opened new Sonoma Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of -2 holders.
  • The largest Sonoma Pharmaceuticals buyer in Q2 2023 was Two Sigma Securities, an estimated $53.5K added.
  • The largest Sonoma Pharmaceuticals seller in Q2 2023 was Millennium Management, an estimated $23K sold.

Based on aggregated 13F filings for Q2 2023.